Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2013

View Archived Issues

A prognostic peptide-based signature for end-stage renal disease in fetal urinary output

Medimmune to acquire Amplimmune

AiCuris presents a novel class of antibacterial compound with potent activity

An oral multikinase inhibitor shows potent antiangiogenic activity in vivo

Carolus and TAP seek to validate RANTES:Pf-4 as CT-2009 target

Acucela's SEATTLE study reaches half way enrollment

TRPM8 blockade as a potential new treatment strategy for urinary bladder disorders

Licensing and codevelopment agreement for NovaBiotics' first-in-class antifungal peptide

Lee's Pharmaceutical submits CTA to expand the APEX study to China

Orexo updates on OX-51 phase II dose-finding study

Arena Pharmaceuticals completes phase Ib APD-811 trial

FDA accepts for review dabigatran supplemental NDA

U.K.'s NICE does not recommend everolimus use by NHS

Cepheid's Xpert MTB/RIF test categorized by FDA

The University of Virgina presents new sphingosine kinase inhibitors

Novel EGFR inhibitors disclosed by Taiho Pharmaceutical

Scientists at Innate Pharma divulge new MAbs for cancer

Sunovion Pharmaceuticals discloses new antipsychotic agents

FDA extends PDUFA goal date for Xiaflex

Teva decides not to license RX-3117 from Rexahn

Japanese launch for Bonviva injection

Phase II trial planned for CF-102 in hepatocellular carcinoma

Daiichi Sankyo files marketing application for Ranmark in Japan

Grifols and Aradigm close worldwide licensing agreement for inhaled formulations of ciprofloxacin

Europe Commission approves Eylea for visual impairment complications following CRVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...